| Literature DB >> 35057544 |
Marialena Chrysanthou1, Ignacio Miro Estruch2, Ivonne M C M Rietjens2, Harry J Wichers1,3, Tamara Hoppenbrouwers3,4.
Abstract
Advanced glycation end products (AGEs) can be present in food or be endogenously produced in biological systems. Their formation has been associated with chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The implication of AGEs in neurodegeneration is related to their ability to bind to AGE-specific receptors and the ability of their precursors to induce the so-called "dicarbonyl stress", resulting in cross-linking and protein damage. However, the mode of action underlying their role in neurodegeneration remains unclear. While some research has been carried out in observational clinical studies, further in vitro studies may help elucidate these underlying modes of action. This review presents and discusses in vitro methodologies used in research on the potential role of AGEs in neuroinflammation and neurodegeneration. The overview reveals the main concepts linking AGEs to neurodegeneration, the current findings, and the available and advisable in vitro models to study their role. Moreover, the major questions regarding the role of AGEs in neurodegenerative diseases and the challenges and discrepancies in the research field are discussed.Entities:
Keywords: AGEs; advanced glycation end products; blood–brain barrier; in vitro models; inflammation; neurodegeneration; neuroinflammation; neuro–immune axis
Mesh:
Substances:
Year: 2022 PMID: 35057544 PMCID: PMC8777776 DOI: 10.3390/nu14020363
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1The three stages of Maillard reaction and the formation of AGEs and α-dicarbonyls.
Figure 2Concepts in AGE-mediated neurodegeneration. Circulating AGEs can disrupt the brain endothelial barrier and enter the brain. There they activate microglia and cause them to initiate an inflammatory response that can affect neuronal survival. AGEs can also have direct cytotoxic effects on neurons. Moreover, some studies have shown the intracellular formation of AGEs in microglia and neurons. However, the mechanisms remain still unclear. This figure was created with Servier Medical Art templates, licensed under a Creative Commons Attribution 3.0 Unported License; Available online: https://smart.servier.com (accessed on 23 July 2021).
Main outcomes from existing studies on AGEs or other RAGE ligands, in which monocultures were used as models of neuroinflammation, neurodegeneration, and BBB.
| Relevant Endpoint | Cell Type | Line Name | Origin | Exposed to | Outcome | Reference |
|---|---|---|---|---|---|---|
| Neuroinflammation/inflammation | Microglia | BV2 | mouse | MGO-BSA | ↑ •NO, ROS, NLRP3, NF-κΒ, TNF-α, IL-6, MAPKs, RAGE, COX-2 | [ |
| N11 | mouse | Glu-BSA | Microglial activation, ↑ •NO, IL-6, MCP-1, TNF-α | [ | ||
| Glu-CEA | ↑ •NO, iNOS, TNF-α, IL_6 | [ | ||||
| HMC3 | Human | Glu-HSA | ↑ •NO, apoptosis | [ | ||
| Glu-BSA | Activated microglia (↑ Glu-5, CR3/43), ↑ RAGE, TNF-α | [ | ||||
| HMO6 | Human | Aβ peptide | ↑ RAGE, synthesis of AGE-albumin | [ | ||
| Monocytes/macrophages | THP-1 | Human | Glu-BSA | ↑ VEGF, IL-6, TNF-α, iNOS, RAGE, promoted M1 phenotype | [ | |
| MG-H1 | ↑ Adhesion to HUVECs | [ | ||||
| S100b | ↑ RAGE, MCP-1, IP-10, COX-2, NOX2, O2•, NF-κB activation. | [ | ||||
| Hypoxia | ↑ AGEs, MCP-1, RAGE, NF-κΒ, Μ1 phenotype | [ | ||||
| MGO | ↑ secretion of AGEs, glycation of cell surface proteins, unchanged ROS and RAGE, ↑ IL-1β, IL-8, TNF-α | [ | ||||
| MGO-BSA | ↑ COX2, TNF-α, M-CSF | [ | ||||
| Neurodegeneration/neurotoxicity | Neuronal | PC12 | Rat | Ribosylated-BSA | ↑ apoptosis, iNOS, COX2, pp38 | [ |
| Glu-BSA | ↑ apoptosis, RAGE, NF-κΒ | |||||
| Glu + MGO | ↑ protein carbonyls, ROS, RAGE, NF-κΒ | |||||
| Neuro2A | mouse | MGO | ↑ ROS, apoptosis, intracellular CML | [ | ||
| SH-SY5Y | human | AGE-BSA | ↑ RAGE, ROS, apoptosis, NF-κB, AMPK | [ | ||
| MGO | ↑ apoptosis, ROS, MDA, mitochondrial damage | [ | ||||
| Ribosylated α-synuclein | ↑ ROS | [ | ||||
| GA | ↑ AGE accumulation intracellularly, apoptosis, VEGF, TGF-β, phosphorylated tau | [ | ||||
| LUHMES | Human | AGE-BSA | ↑ RAGE, MAPKs, Bax | [ | ||
| BBB | Endothelial | bEnd.3 | Mouse | MGO-BSA | ↑ monolayer permeability, ROS | [ |
| BMECs | Human or animal | AGE-BSA | ↓claudin-5, TEER, | [ | ||
| HUVECs | human | Glu-BSA | ↓GSH activity | [ | ||
| Glycated insulin | ↓viability, Bcl-2 | [ | ||||
| MGO | ↑ ROS, apoptosis, Bax, MAPKs | [ |
↑: increased, ↓: decreased.
The advisable in vitro models per endpoint of interest. The endpoints in which the role of AGEs in neurodegeneration can be studied are neuroinflammation, neurotoxicity, and BBB.
| Advisable Model per Endpoint | Advantages | Disadvantages | References | |
|---|---|---|---|---|
| Neuroinflammation | HMC3 microglial line | Human line, RAGE expression, M1 and M2 phenotype, existing literature on AGEs effects | No aggregate formation | [ |
| Co-culture of neurons with microglia in transwell | Well-established models, | No aggregate formation | [ | |
| iPSC-derived microglia | Patient-derived cells with diseased genotypic background, formation of aggregates | Non-high throughput, expensive, laborious procedure, low efficiency of differentiated cells | [ | |
| NF-κΒ reporter cell lines | Very informative to understand AGE signalling | Most of the available lines are no brain-related lines | [ | |
| Neurotoxicity | SH-SY5Y | Human line, extensively used in AGE-studies, RAGE expression, intracellular formation of AGEs, differentiated to dopaminergic neurons, Lewy body formation observed | Multiple differentiation protocols exist, possible unstable genome due to cancerous origin | [ |
| iPSC derived neurons | Patient-derived cells with diseased genotypic background, formation of aggregates | Non-high throughput, expensive, laborious, low efficiency | [ | |
| Nrf-2 reporter cell lines | Very informative to understand AGE signalling and the potential protective effects of AGE inhibitors | No brain-related lines are available | [ | |
| BBB | hCMEC/D3 | Human line, expression of endothelial junctional markers and transporters, RAGE expression, applied in AGE and ND research, widely used and characterised BBB model | Exhibit lower TEER than primary endothelial cells | [ |
| iPSC derived brain endothelial cells | Patient-derived cells with diseased genotypic background, formation of aggregates, high TEER values | Non-high-throughput, expensive, laborious, low efficiency, reproducibility not confirmed | [ | |
| Co-cultures of brain endothelial cells with microglia in transwells | Well-established models, paracrine communication between cell types, | No aggregate formation, complicated | [ | |
| BBB-on-a-chip | 3D, fluid shear stress, ECM, paracrine and juxtacrine signalling, combination of cell types | Complex | [ |